Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.
The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Selinexor in combination with twice-weekly dexamethasone led to a median overall survival of 15.6 months in patients with heavily pretreated multiple myeloma who had a minimal response or better to the novel agent compared with 1.7 months in those whose disease progressed or had unevaluable responses.
Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.
The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.
Peter Voorhees, MD, discusses the recent data with triplet regimens in late relapsed multiple myeloma and other novel agents shaking up the paradigm.
The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.
Noopur Raje, MD, highlights the multitude of available and emerging options in relapsed myeloma, as well as the key factors for treatment selection in this heterogeneous population.
David Samuel Dicapua Siegel, MD, highlights key research in multiple myeloma and the renewed focus on improving quality of life.
C. Ola Landgren, MD, PhD, shares his expert insight on recent shifts in multiple myeloma management.